<SEC-DOCUMENT>0001493152-25-024279.txt : 20251119
<SEC-HEADER>0001493152-25-024279.hdr.sgml : 20251119
<ACCEPTANCE-DATETIME>20251119163051
ACCESSION NUMBER:		0001493152-25-024279
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20251117
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251119
DATE AS OF CHANGE:		20251119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		251499736

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:APYX="http://apyxmedical.com/20251117">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_APYX_apyxmedical.com_20251117 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20251117_20251117 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0000719135 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000004" name="dei:EntityCentralIndexKey">0000719135</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="apyx-20251117.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-17</xbrli:startDate>
        <xbrli:endDate>2025-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20251117__20251117_zU1FJECWmChi"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--DocumentPeriodEndDate_c20251117__20251117_zviAf4x0JKWg"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November
17, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (date of earliest event reported)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img src="form8-k_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20251117__20251117_zTouAZuWj4ad"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000011" name="dei:EntityRegistrantName">APYX
MEDICAL CORPORATION</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20251117__20251117_zsRYqAT69Osk"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20251117__20251117_zFlIfkWFa7N7"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000013" name="dei:EntityFileNumber">001-31885</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20251117__20251117_znjCgnUPLxf8"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000014" name="dei:EntityTaxIdentificationNumber">11-2644611</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20251117__20251117_zLQUWbsyHMb1"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000015" name="dei:EntityAddressAddressLine1">5115
Ulmerton Road</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressCityOrTown_c20251117__20251117_zC9u8pYfc9U3"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000016" name="dei:EntityAddressCityOrTown">Clearwater</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20251117__20251117_zFLtsZUIEyN9"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20251117__20251117_zD44blTOclvb"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000018" name="dei:EntityAddressPostalZipCode">33760</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_906_edei--CityAreaCode_c20251117__20251117_zm2E2YZzFDW9"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000019" name="dei:CityAreaCode">727</ix:nonNumeric></span>)
<span id="xdx_903_edei--LocalPhoneNumber_c20251117__20251117_zpYHLKIx4Bl3"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000020" name="dei:LocalPhoneNumber">384-2323</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--WrittenCommunications_c20251117__20251117_ztzwuWpdnPM7"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SolicitingMaterial_c20251117__20251117_zGC3g5wegxx4"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20251117__20251117_zC6gQAwPMU5e"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20251117__20251117_zasoLOnAmTb5"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20251117__20251117_zTgTBIp1Vef9"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20251117__20251117_zinZdmjqh3pd"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000026" name="dei:TradingSymbol">APYX</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20251117__20251117_zWPos2Fdr5B7"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Global Select Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20251117__20251117_zGz50Teo0jii"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2025, Apyx Medical Corporation (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting
Agreement&#8221;) with Lucid Capital Markets, LLC (the &#8220;Underwriter&#8221;) pursuant to which the Company will issue and sell to
the Underwriter pursuant to the Underwriting Agreement 2,762,431 shares (the &#8220;Shares&#8221;) of common stock, par value
$0.001 per share (the &#8220;Common Stock&#8221;) at an offering price of $3.62 and grant to the Underwriter an option for the
issuance and sale of up to 414,365 additional Shares (the &#8220;Option&#8221;) to be sold by the Company (the &#8220;Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering closed</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
 November 19,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025.
The aggregate gross proceeds to the Company from the Offering will be approximately $9.4</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting an underwriting discount of 6.0%</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the price to the public, but before deducting expenses payable
by the Company in connection with the Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expects to use the net proceeds from the Offering for working capital and general corporate purposes, including expanding its
sales and marketing, capital expenditures, acquisitions of complementary businesses, products, or technologies and repaying indebtedness
it may incur from time to time. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company and the Underwriter, customary conditions
to closing, and customary indemnification obligations of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of the Shares were made pursuant to a prospectus supplement to a Registration Statement on Form S-3 (File No. 333-268532), which
was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 22, 2022 and declared effective by the SEC
on December 2, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The description of the terms of the Underwriting Agreement set forth above is qualified in its entirety by reference to
the full text of the Underwriting Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the legal opinion, including the related consent, of Ruskin Moscou Faltischek, P.C. relating to the legality of the issuance
and sale of Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 17, 2025, the Company issued a press release announcing the launch of the Offering, and on November 18, 2025,
the Company issued a press release announcing the pricing of the Offering. The launch and pricing press releases are attached hereto
as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>

  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Underwriting Agreement between Company and Lucid Capital Markets, LLC, dated November 18, 2025.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Ruskin Moscou Faltischek, P.C.</a></span></td></tr>


<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Ruskin Moscou Faltischek, P.C. (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Launch
    Press Release, dated November 17, 2025.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-2.htm">Pricing
    Press Release, dated November 18, 2025.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File embedded within the Inline XBRL document</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APYX
    MEDICAL CORPORATION</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Date:
    November 19, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew Hill</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </span></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Hill</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Secretary and Treasurer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LW4dzMEuHSrilDGGeFtdlOLWjLT+PZJvad0QQyAk53wnQkzEipa6RYbDvCqgxq5vlUOo8IyM5oTeka83GfhZ4UVbx8q4Yf2BOXkGPTObyqO/D867tthkIGUo0zBOIEqyJIVyK4KvnpM56waN06oFZRoomXrW6BS/xoRaPclQ9xo+7ZGtJuPjptEovyGOZAw7uqsH8dVCUeQimAwViBXTrfeuxdOh+ZKwaLHz7+xI/zv4AM9sSmM= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2,762,431</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>
SHARES <FONT STYLE="text-transform: uppercase">of Common Stock and </FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>0</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>
PRE-FUNDED Warrants of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APYX
MEDICAL CORPORATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
November 18, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucid
Capital Markets, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Representative of the</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Several underwriters, if any, named in <U>Schedule I</U> hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
Lucid Capital Markets, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">570
Lexington Avenue, 40<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Apyx Medical Corporation, a company incorporated under the laws of Delaware (the &ldquo;<U>Company</U>&rdquo;), hereby confirms
its agreement (this &ldquo;<U>Agreement</U>&rdquo;) with the several underwriters (such underwriters, including the Representative (as
defined below), the &ldquo;<U>Underwriters</U>&rdquo; and each an &ldquo;<U>Underwriter</U>&rdquo;) named in <U>Schedule I</U> hereto
for which Lucid Capital Markets, LLC is acting as representative to the several Underwriters (the &ldquo;<U>Representative</U>&rdquo;
and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term
Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is understood that the several Underwriters are to make a public offering of the Securities as soon as the Representative deems it advisable
to do so. The Securities are to be initially offered to the public at the public offering price set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">It
is further understood that you will act as the Representative for the Underwriters in the offering and sale of the Closing Securities
and, if any, the Option Shares in accordance with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled
by or is under common control with such Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Closing Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the hour and the date on the Trading Day on which all conditions precedent to (i) the Underwriters&rsquo; obligations
to pay the Closing Purchase Price and (ii) the Company&rsquo;s obligations to deliver the Closing Securities, in each case, have been
satisfied or waived, but in no event later than 10:00 a.m. (New York City time) on the first (1st) Trading Day following the date hereof
(or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed on a day that is not a Trading Day
or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day) or at such earlier time as shall be
agreed upon by the Representative and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b), which aggregate purchase price shall be net
of the underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Securities</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Shares</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Warrants</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Auditor</U>&rdquo; means RSM US LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Ruskin Moscou Faltischek, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Execution
Date</U>&rdquo; shall mean the date on which the parties execute and enter into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan or grant duly adopted for such purpose by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company,
(b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement (including any underwriter
warrants issuable hereunder, if any), provided that such securities have not been amended since the date of this Agreement to increase
the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the
term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and
carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition
period in 4.18(a) herein, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which
is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the
Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FINRA</U>&rdquo;
means the Financial Industry Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
means (a) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the
ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c)
the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreements</U>&rdquo; means the lock-up agreements that are delivered on the date hereof by each of the Company&rsquo;s officers and
directors, in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the
Company and the Subsidiaries, taken as a whole or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Offering</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Closing Date</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Closing Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(b), which aggregate purchase price shall
be net of the underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Shares</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(a)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Underwriters in accordance with
Section 2.1(a)(ii) and Section 2.2, which Pre-Funded Warrants shall be exercisable immediately until exercised in full, in the form of
<U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus supplement relating to the Public Securities included in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the base prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means, any supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the
Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means, collectively, the various parts of the registration statement prepared by the Company on Form S-3 (File No.
333-268532) with respect to the Securities, each as amended as of the date hereof, including the Preliminary Prospectus, Prospectus and
Prospectus Supplement, if any, and all exhibits filed with or incorporated by reference into such registration statement, and includes
any Rule 462(b) Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
462(b) Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities,
which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated
by the Commission pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Closing Securities, the Option Shares and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Share
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means, collectively, the shares of Common Stock delivered to the Underwriters in accordance with Section 2.1(a)(i) and Section 2.2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, the Lock-Up Agreements, and any other documents or agreements executed
in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Broadridge Financial Solutions, Inc., the current transfer agent of the Company, and any successor transfer agent
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>PURCHASE
AND SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon the terms and subject to the conditions set forth herein, the Company agrees to sell in the aggregate 2,762,431 shares of
Common Stock and Pre-Funded Warrants exercisable for an aggregate of 0 shares of Common Stock, and each Underwriter agrees to
purchase, severally and not jointly, at the Closing, the following securities of the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the number of shares of Common Stock (the &ldquo;<U>Closing Shares</U>&rdquo;) set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Pre-Funded Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereof (the &ldquo;<U>Closing Warrants</U>&rdquo; and, collectively with the Closing Shares, the &ldquo;<U>Closing Securities</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The aggregate purchase price for the Closing Securities shall equal the amount set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereto (the &ldquo;<U>Closing Purchase Price</U>&rdquo;). The purchase price for one Share shall be $3.4028 (the &ldquo;<U>Share
Purchase Price</U>&rdquo;) and the purchase price for each Warrant Share underlying the Pre-Funded Warrants shall be the Share Purchase
Price less $0.001 per Warrant Share (the &ldquo;<U>Warrant Purchase Price</U>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
On the Closing Date, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available
funds equal to such Underwriter&rsquo;s Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter
its respective Closing Securities and the Company shall deliver the other items required pursuant to Section 2.3 deliverable at the Closing.
Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the offices of EGS or
such other location as the Company and Representative shall mutually agree. The Securities are to be offered initially to the public
at the offering price set forth on the cover page of the Prospectus (the &ldquo;<U>Offering</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company acknowledges and agrees that, with respect to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered
by a Holder (as defined in the Pre-Funded Warrants) on or prior to 12:00 p.m. (New York City time) on the Closing Date, which Notice(s)
of Exercise may be delivered at any time after the time of execution of this Agreement, the Company shall deliver the Warrant Shares
subject to such notice(s) to the Holder by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant
Share Delivery Date (as defined in the Pre-Funded Warrants). The Company acknowledges and agrees that the Holders are third-party beneficiaries
of this covenant of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Option to Purchase Additional Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
For the purposes of covering any over-allotments in connection with the distribution and sale of the Closing Securities, the Representative
is hereby granted an option (the &ldquo;<U>Option</U>&rdquo;) to purchase, in the aggregate, up to 414,365 shares of Common Stock
(the &ldquo;<U>Option Shares</U>&rdquo;) at the Share Purchase Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In connection with an exercise of the Option, the purchase price to be paid for the Option Shares is equal to the product of the Share
Purchase Price multiplied by the number of Option Shares to be purchased (the aggregate purchase price to be paid on an Option Closing
Date, the &ldquo;<U>Option Closing Purchase Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Option granted pursuant to this Section 2.2 may be exercised by the Representative as to all (at any time) or any part (from time
to time) of the Option Shares within 45 days after the Execution Date. An Underwriter will not be under any obligation to purchase any
Option Shares prior to the exercise of the Option by the Representative. The Option granted hereby may be exercised by the giving of
oral notice to the Company from the Representative, which must be confirmed in writing by overnight mail or electronic transmission setting
forth the number of Option Shares to be purchased and the date and time for delivery of and payment for the Option Shares (each, an &ldquo;<U>Option
Closing Date</U>&rdquo;), which will not be later than one (1) full Business Day after the date of the notice or such other time as shall
be agreed upon by the Company and the Representative, at the offices of EGS or at such other place (including remotely by other electronic
transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Option Shares does
not occur on the Closing Date, each Option Closing Date will be as set forth in the notice. Upon exercise of the Option, the Company
will become obligated to convey to the Underwriters, and, subject to the terms and conditions set forth herein, the Underwriters will
become obligated to purchase, the number of Option Shares specified in such notice. The Representative may cancel the Option at any time
prior to the expiration of the Option by written notice to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Deliveries</U>. The Company shall deliver or cause to be delivered to each Underwriter (if applicable) the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
At the Closing Date, the Closing Shares and, as to each Option Closing Date, if any, the applicable Option Shares, which shares shall
be delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
At the Closing Date, the Closing Warrants in certificated form registered in the name or names and in such authorized denominations as
the applicable Underwriter may request in writing at least one Business Day prior to the Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
At the Closing Date, a legal opinion of Company Counsel addressed to the Underwriters, including, without limitation, a negative assurance
letter, substantially in the form and substance reasonably satisfactory to the Representative attached hereto and as to the Closing Date
and as to each Option Closing Date, if any, a bring-down opinion from Company Counsel in form and substance reasonably satisfactory to
the Representative, including, without limitation, a negative assurance letter, addressed to the Underwriters and in form and substance
satisfactory to the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Contemporaneously herewith, a cold comfort letter, addressed to the Underwriters and in form and substance satisfactory in all respects
to the Representative from the Company Auditor dated, respectively, as of the date of this Agreement and a bring-down letter dated as
of the Closing Date and each Option Closing Date, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
On the Closing Date and on each Option Closing Date, the duly executed and delivered Officer&rsquo;s Certificate, in form and substance
reasonably satisfactory to the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
On the Closing Date and on each Option Closing Date, the duly executed and delivered Secretary&rsquo;s Certificate, in form and substance
reasonably satisfactory to the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
On the Closing Date and on each Option Closing Date, if any, the duly executed and delivered Chief Financial Officer&rsquo;s Certificate,
substantially in the form and substance reasonably satisfactory to the Representative; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
Contemporaneously herewith, the duly executed and delivered Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
<U>Closing Conditions</U>. The respective obligations of each Underwriter hereunder in connection with the Closing and each Option Closing
Date are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects when made and on the date in question (other than representations and warranties of the Company
already qualified by materiality, which shall be true and correct in all respects) of the representations and warranties of the Company
contained herein (unless as of a specific date therein);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the date in question shall have been
performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.3 of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
the Registration Statement shall be effective on the date of this Agreement and at each of the Closing Date and each Option Closing Date
(subject to the filing of a Universal Shelf Registration Statement on Form S-3, filed by the Company to maintain the continued effectiveness
of the Registration Statement), if any, no stop order suspending the effectiveness of the Registration Statement shall have been issued
and no proceedings for that purpose shall have been instituted or shall be pending or contemplated by the Commission and any request
on the part of the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
by the Execution Date, if required by FINRA, the Underwriters shall have received clearance from FINRA as to the amount of compensation
allowable or payable to the Underwriters as described in the Registration Statement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Closing Shares, the Option Shares and the Warrant Shares have been approved for listing on the Trading Market; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been no material adverse change or
development involving a prospective material adverse change in the condition or prospects or the business activities, financial or otherwise,
of the Company from the latest dates as of which such condition is set forth in the Preliminary Prospectus, Registration Statement Prospectus
and Prospectus Supplement; (ii) no action suit or proceeding, at law or in equity, shall have been pending or threatened against the
Company or any Affiliate of the Company before or by any court or federal or state commission, board or other administrative agency wherein
an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial condition
or income of the Company, except as set forth in the Preliminary Prospectus, Registration Statement, Prospectus and Prospectus Supplement;
(iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened
by the Commission; and (iv) the Preliminary Prospectus, Registration Statement, Prospectus and Prospectus Supplement and any amendments
or supplements thereto shall contain all material statements which are required to be stated therein in accordance with the Securities
Act and the rules and regulations thereunder and shall conform in all material respects to the requirements of the Securities Act and
the rules and regulations thereunder, and none of the Preliminary Prospectus, Registration Statement, Prospectus or the Prospectus Supplement
nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Execution Date,
as of the Closing Date and as of each Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect Subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary, and all of the issued and outstanding shares of
capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe
for or purchase securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents to which the Company is a party and otherwise to carry out
its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by
the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary
action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document
to which the Company is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filing
with the Commission of the Prospectus Supplement and (ii) such filings as are required to be made under applicable state securities laws
(collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Registration Statement</U>. The Company has filed with the Commission the Registration Statement under the Securities Act, which became
effective on December 2, 2022 (the &ldquo;<U>Effective Date</U>&rdquo;), for the registration under the Securities Act of the Securities.
At the time of such filing, the Company met the requirements of Form S-3 under the Securities Act. The Registration Statement meets the
requirements set forth in Rule 415(a)(1)(x) under the Securities Act and complies with said Rule and the Prospectus Supplement will meet
the requirements set forth in Rule 424(b). The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction
requirements with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12)
months prior to this offering, as set forth in General Instruction I.B.6 of Form S-3. The Company has advised the Representative of all
further information (financial and other) with respect to the Company required to be set forth therein in the Registration Statement,
Preliminary Prospectus, Prospectus and Prospectus Supplement. Any reference in this Agreement to the Registration Statement, Preliminary
Prospectus, the Prospectus or the Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference
therein which were filed under the Exchange Act, on or before the date of this Agreement, or the issue date of the Prospectus, the Preliminary
Prospectus or the Prospectus Supplement, as the case may be; and any reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to the Registration Statement, the Preliminary Prospectus, the Prospectus or the Prospectus
Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of this Agreement,
or the issue date of the Preliminary Prospectus, the Prospectus or the Prospectus Supplement, as the case may be, deemed to be incorporated
therein by reference. All references in this Agreement to financial statements and schedules and other information which is &ldquo;contained,&rdquo;
&ldquo;included,&rdquo; &ldquo;described,&rdquo; &ldquo;referenced,&rdquo; &ldquo;set forth&rdquo; or &ldquo;stated&rdquo; in the Registration
Statement, the Prospectus, the Preliminary Prospectus, or the Prospectus Supplement (and all other references of like import) shall be
deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated
by reference in the Registration Statement, the Prospectus, the Preliminary Prospectus, or the Prospectus Supplement, as the case may
be. No stop order suspending the effectiveness of the Registration Statement or the use of the Preliminary Prospectus, the Prospectus
or the Prospectus Supplement has been issued, and no proceeding for any such purpose is pending or has been initiated or, to the Company&rsquo;s
knowledge, is threatened by the Commission. For purposes of this Agreement, &ldquo;<U>free writing prospectus</U>&rdquo; has the meaning
set forth in Rule 405 under the Securities Act. The Company will not, without the prior consent of the Representative, prepare, use or
refer to, any free writing prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Issuance of Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrant
Shares, when issued in accordance with the terms of the Pre-Funded Warrants, will be validly issued, fully paid and nonassessable, free
and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of
shares of Common Stock issuable pursuant to this Agreement and the Pre-Funded Warrants. The holder of the Securities will not be subject
to personal liability by reason of being such holders. The Securities are not and will not be subject to the preemptive rights of any
holders of any security of the Company or similar contractual rights granted by the Company. All corporate action required to be taken
for the authorization, issuance and sale of the Securities has been duly and validly taken. The Securities conform in all material respects
to all statements with respect thereto contained in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Capitalization</U>. The capitalization of the Company is as set forth in the SEC Reports. The Company has not issued any capital stock
since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under
the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee
stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most
recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase
and sale of the Securities or as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any
Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to
issue additional shares of Common Stock or Common Stock Equivalents or the capital stock of any Subsidiary. The issuance and sale of
the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other
than the Underwriters). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts
the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any
Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar
provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may
become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom
stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are
duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws,
and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
The authorized shares of the Company conform in all material respects to all statements relating thereto contained in the Registration
Statement and the Prospectus. The offers and sales of the Company&rsquo;s securities were at all relevant times either registered under
the Securities Act and the applicable state securities or Blue Sky laws or, based in part on the representations and warranties of the
purchasers, exempt from such registration requirements. No further approval or authorization of any stockholder, the Board of Directors
or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Preliminary Prospectus,
the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely
basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such
extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act
and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments. The agreements and documents described in the Preliminary Prospectus, the Registration Statement, the Prospectus,
the Prospectus Supplement and the SEC Reports conform to the descriptions thereof contained therein and there are no agreements or other
documents required by the Securities Act and the rules and regulations thereunder to be described in the Preliminary Prospectus, the
Registration Statement, the Prospectus, the Prospectus Supplement or the SEC Reports or to be filed with the Commission as exhibits to
the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described)
to which the Company is a party or by which it is or may be bound or affected and (i) that is referred to in the Preliminary Prospectus,
the Registration Statement, the Prospectus, the Prospectus Supplement or the SEC Reports, or (ii) is material to the Company&rsquo;s
business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable
against the Company and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms, except (x) as such
enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally,
(y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and
(z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses
and to the discretion of the court before which any proceeding therefore may be brought. None of such agreements or instruments has been
assigned by the Company, and neither the Company nor, to the best of the Company&rsquo;s knowledge, any other party is in default thereunder
and, to the best of the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both,
would constitute a default thereunder. To the best of the Company&rsquo;s knowledge, performance by the Company of the material provisions
of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or
decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses,
including, without limitation, those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has been
no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the
Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the
ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial
statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting,
(iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock, (v) the Company has not issued any equity securities to
any officer, director or Affiliate, except pursuant to existing Company stock option plans and (vi) no officer or director of the Company
has resigned from any position with the Company. The Company does not have pending before the Commission any request for confidential
treatment of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries
or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least one (1) Trading Day prior to the date that this representation is made. Unless otherwise disclosed in an SEC Report filed prior
to the date hereof, the Company has not: (i) issued any securities or incurred any liability or obligation, direct or contingent, for
borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;) which (i) adversely affects or challenges the legality, validity or enforceability of
any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected
to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the
subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state,
local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages
and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any applicable statute, rule, ordinance or regulation of any
governmental authority, including without limitation all applicable foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could
not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (each, a &ldquo;<U>Material
Permit</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit. The disclosures in the Registration Statement concerning the effects of Federal, State, local and all foreign
regulation on the Company&rsquo;s business as currently contemplated are correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. Except as set forth in the SEC Reports, the Company and the Subsidiaries have good and marketable title in fee
simple to, or have valid and marketable rights to lease or otherwise use, all real property and all personal property that is material
to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially
affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company
and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor
in accordance with GAAP, and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held
under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company
and the Subsidiaries are in compliance in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to do so would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.
To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another
Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that
it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from, any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except as set forth in the Preliminary Prospectus and the Prospectus Supplement, no brokerage or finder&rsquo;s
fees or commissions are or will be payable by the Company, any Subsidiary or Affiliate of the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the
Transaction Documents. To the Company&rsquo;s knowledge, there are no other arrangements, agreements or understandings of the Company
or, to the Company&rsquo;s knowledge, any of its stockholders that may affect the Underwriters&rsquo; compensation, as determined by
FINRA. The Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s
fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons
who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation
or association with any FINRA member, within the twelve months prior to the Execution Date. None of the net proceeds of the Offering
will be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. Except as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to
effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is
or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such
Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance
with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository
Trust Company or another established clearing corporation and the Company is current in payment of the fees of the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable as a result of the Underwriters and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure; 10b-5</U>. The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits
and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, if any,
at the time it became effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable rules
and regulations under the Securities Act and did not and, as amended or supplemented, if applicable, will not, contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
The Preliminary Prospectus, Prospectus and the Prospectus Supplement, each as of its respective date, comply in all material respects
with the Securities Act and the Exchange Act and the applicable rules and regulations. Each of the Preliminary Prospectus, Prospectus
and the Prospectus Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of
a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. The SEC Reports, when they were filed with the Commission, conformed in all material respects to
the requirements of the Exchange Act and the applicable rules and regulations, and none of such documents, when they were filed with
the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements
therein (with respect to the SEC Reports incorporated by reference in the Preliminary Prospectus, Prospectus or the Prospectus Supplement),
in light of the circumstances under which they were made not misleading; and any further documents so filed and incorporated by reference
in the Preliminary Prospectus, Prospectus or the Prospectus Supplement, when such documents are filed with the Commission, will conform
in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, as applicable, and will not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of
the circumstances under which they were made not misleading. No post-effective amendment to the Registration Statement reflecting any
facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the information
set forth therein is required to be filed with the Commission. There are no documents required to be filed with the Commission in connection
with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed
within the requisite time period. There are no contracts or other documents required to be described in the Preliminary Prospectus, Prospectus
or the Prospectus Supplement, or to be filed as exhibits or schedules to the Registration Statement, which have not been described or
filed as required. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken
as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause
this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval
provisions of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. The SEC Reports sets forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. Neither the
Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration
Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of
such consolidated financial statements. The term &ldquo;taxes&rdquo; mean all federal, state, local, foreign, and other net income, gross
income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll,
employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments,
or charges of any kind whatsoever, together with any interest and any penalties, additions to tax, or additional amounts with respect
thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements, and other documents required to be filed
in respect to taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA. The Company
has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all
material respects with the FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. To the knowledge and belief of the Company, the Company Auditor (i) is an independent registered public accounting
firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the
Company&rsquo;s Annual Report for the fiscal year ending December 31, 2025. The Company Auditor has not, during the periods covered by
the financial statements included in the Prospectus, provided to the Company any non-audit services, as such term is used in Section
10A(g) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Reserved.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<FONT STYLE="letter-spacing: -0.15pt"><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s
knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions
administered by the Office of Foreign Assets Control of the U.S. Treasury Department.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<FONT STYLE="letter-spacing: -0.15pt"><U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real
property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall
so certify upon the Representative&rsquo;s request.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<FONT STYLE="letter-spacing: -0.15pt"><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates
is subject to the Bank Holding Company Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors
of the Federal Reserve System (the &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates
owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a
bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<FONT STYLE="letter-spacing: -0.15pt"><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted
at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively,
the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company or any Subsidiary, threatened.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>D&amp;O Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires completed by each of
the Company&rsquo;s directors and officers immediately prior to the Offering and in the Lock-Up Agreement provided to the Underwriters
is true and correct in all respects and the Company has not become aware of any information which would cause the information disclosed
in such questionnaires become inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>FINRA Affiliation</U>. To the Company&rsquo;s knowledge, no officer, director or any beneficial owner of 5% or more of the Company&rsquo;s
unregistered securities has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with
the rules and regulations of FINRA) that is participating in the Offering. The Company will advise the Representative and EGS if it learns
that any officer, director or owner of 5% or more of the Company&rsquo;s outstanding shares of Common Stock or Common Stock Equivalents
is or becomes an affiliate or associated person of a FINRA member firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Officers&rsquo; Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to the Representative
or EGS shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Board of Directors</U>. The Board of Directors is comprised of the persons set forth under the SEC Reports. The qualifications of
the persons serving as board members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002
and the rules promulgated thereunder applicable to the Company and the rules of the Trading Market. At least one member of the Board
of Directors qualifies as a &ldquo;financial expert&rdquo; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules
promulgated thereunder and the rules of the Trading Market. In addition, at least a majority of the persons serving on the Board of Directors
qualify as &ldquo;independent&rdquo; as defined under the rules of the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Cybersecurity</U>. There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems
and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company
and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries
have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and
the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have
implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last three (3) years
were, in compliance with all applicable state, federal and foreign data privacy and security laws and regulations, including, without
limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice
of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and
(iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its
subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy
Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph,
social security number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally
identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR;
and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy
Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any
court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all applicable federal, state, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land
surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
AGREEMENTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Amendments to Registration Statement</U>. The Company has delivered, or will as promptly as practicable deliver, to the Underwriters
complete conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part
thereof, and conformed copies of the Registration Statement (without exhibits), the Preliminary Prospectus, the Prospectus and the Prospectus
Supplement, as amended or supplemented, in such quantities and at such places as an Underwriter reasonably requests. Neither the Company
nor any of its directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering material
in connection with the offering and sale of the Public Securities other than the Preliminary Prospectus, the Prospectus, the Prospectus
Supplement, the Registration Statement, and copies of the documents incorporated by reference therein. The Company shall not file any
such amendment or supplement to which the Representative shall reasonably object in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Federal Securities Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Compliance</U>. During the time when a Prospectus is required to be delivered under the Securities Act, the Company will use its best
efforts to comply with all requirements imposed upon it by the Securities Act and the rules and regulations thereunder and the Exchange
Act and the rules and regulations thereunder, as from time to time in force, so far as necessary to permit the continuance of sales of
or dealings in the Securities in accordance with the provisions hereof and the Prospectus. If at any time when a Prospectus relating
to the Securities is required to be delivered under the Securities Act, any event shall have occurred as a result of which, in the opinion
of counsel for the Company or counsel for the Underwriters, the Prospectus, as then amended or supplemented, includes an untrue statement
of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, or if it is necessary at any time to amend the Prospectus to comply
with the Securities Act, the Company will notify the Underwriters promptly and prepare and file with the Commission, subject to Section
4.1 hereof, an appropriate amendment or supplement in accordance with Section 10 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Filing of Final Prospectus Supplement</U>. The Company will file the Prospectus Supplement (in form and substance satisfactory to
the Representative) with the Commission pursuant to the requirements of Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Exchange Act Registration</U>. For a period of three (3) years from the Execution Date, the Company will use its best efforts to maintain
the registration of the Common Stock under the Exchange Act. The Company will not deregister the Common Stock under the Exchange Act
without the prior written consent of the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Free Writing Prospectuses</U>. The Company represents and agrees that it has not made and will not make any offer relating to the
Securities that would constitute an issuer free writing prospectus, as defined in Rule 433 of the rules and regulations under the Securities
Act, without the prior written consent of the Representative. Any such free writing prospectus consented to by the Representative is
herein referred to as a <B>&ldquo;</B><U>Permitted Free Writing Prospectus</U>.&rdquo; The Company represents that it will treat each
Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus&rdquo; as defined in rule and regulations under the Securities
Act, and has complied and will comply with the applicable requirements of Rule 433 of the Securities Act, including timely Commission
filing where required, legending and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Delivery to the Underwriters of Prospectuses</U>. The Company will deliver to the Underwriters, without charge, from time to time
during the period when the Prospectus is required to be delivered under the Securities Act or the Exchange Act such number of copies
of each Prospectus as the Underwriters may reasonably request and pursuant to Rule 172 of the Securities Act, as soon as the Registration
Statement or any amendment or supplement thereto becomes effective, deliver to the Representative two (2) Registration Statements, including
exhibits, and all post-effective amendments thereto and copies of all exhibits filed therewith or incorporated therein by reference and
all consents of certified experts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Effectiveness and Events Requiring Notice to the Underwriters</U>. The Company will use its best efforts to cause the Registration
Statement to remain effective with a current prospectus until the later of nine (9) months from the Execution Date and the date on which
the Pre-Funded Warrants are no longer outstanding, and will notify the Underwriters and holders of the Pre-Funded Warrants immediately
and confirm the notice in writing: (i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance
by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance
by any state securities commission of any proceedings for the suspension of the qualification of the Securities for offering or sale
in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery to
the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v) of the receipt of any comments
or request for any additional information from the Commission; and (vi) of the happening of any event during the period described in
this Section 4.4 that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement or the
Prospectus untrue or that requires the making of any changes in the Registration Statement or the Prospectus in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission
shall enter a stop order or suspend such qualification at any time, the Company will make every reasonable effort to obtain promptly
the lifting of such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Expenses of the Offering</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>General Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and each Option Closing
Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company
under this Agreement, including, but not limited to: (a) all filing fees and communication expenses relating to the registration of the
Securities to be sold in the Offering (including the Option Shares) with the Commission; (b) all FINRA Public Offering Filing System
fees associated with the review of the Offering by FINRA; all fees and expenses relating to the listing of such Closing Shares, Option
Shares and Warrant Shares on the Trading Market and such other stock exchanges as the Company and the Representative together determine;
(c) all fees, expenses and disbursements relating to the registration or qualification of such Securities under the &ldquo;blue sky&rdquo;
securities laws of such states and other foreign jurisdictions as the Representative may reasonably designate (including, without limitation,
all filing and registration fees, and the fees and expenses of Blue Sky counsel); (d) the costs of all mailing and printing of the underwriting
documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters,
Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and
all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably
deem necessary; (e) the costs and expenses of the Company&rsquo;s public relations firm; (f) the costs of preparing, printing and delivering
the Securities; (g) fees and expenses of the Transfer Agent for the Securities (including, without limitation, any fees required for
same-day processing of any instruction letter delivered by the Company); (h) stock transfer and/or stamp taxes, if any, payable upon
the transfer of securities from the Company to the Underwriters; (i) the fees and expenses of the Company&rsquo;s accountants; and (j)
the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives. The Underwriters may also deduct from
the net proceeds of the Offering payable to the Company on the Closing Date, or each Option Closing Date, if any, the expenses set forth
herein to be paid by the Company to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Expenses of the Representative</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.5(a),
on the Closing Date it will reimburse to the Representative for its out-of-pocket expenses, including, without limitation, the fees and
expenses of counsel of the Representative, in connection with the Offering, up to $100,000 in the aggregate by deduction from the proceeds
of the Offering contemplated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Application of Net Proceeds</U>. The Company will apply the net proceeds from the Offering received by it in a manner consistent with
the application described under the caption &ldquo;Use of Proceeds&rdquo; in the Prelimianry Prospectus and Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Delivery of Earnings Statements to Security Holders</U>. The Company will make generally available to its security holders as soon
as practicable, but not later than the first day of the fifteenth full calendar month following the Execution Date, an earnings statement
(which need not be certified by independent public or independent certified public accountants unless required by the Securities Act
or the Rules and Regulations under the Securities Act, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the
Securities Act) covering a period of at least twelve consecutive months beginning after the Execution Date..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Stabilization</U>. Neither the Company, nor, to its knowledge, any of its employees, directors or shareholders (without the consent
of the Representative) has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Internal Controls</U>. The Company will maintain a system of internal accounting controls sufficient to provide reasonable assurances
that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded
as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets;
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Accountants</U>. The Company shall continue to retain a nationally recognized independent certified public accounting firm for a period
of at least three years after the Execution Date. The Underwriters acknowledge that the Company Auditor is acceptable to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>FINRA</U>. The Company shall advise the Underwriters (who shall make an appropriate filing with FINRA) if it is aware that any 5%
or greater shareholder of the Company becomes an affiliate or associated person of an Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>No Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual and commercial in nature, based on arms-length negotiations and that neither the Underwriters nor their affiliates or any
selected dealer shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its
affiliates in connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding anything in this
Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the success of the Offering
that are not limited to the difference between the price to the public and the purchase price paid to the Company by the Underwriters
for the shares and the Underwriters have no obligation to disclose, or account to the Company for, any of such additional financial interests.
The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters
with respect to any breach or alleged breach of fiduciary duty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Warrant Shares</U>. If all or any portion of a Pre-Funded Warrant is exercised at a time when there is an effective registration statement
to cover the issuance of the Warrant Shares or if the Pre-Funded Warrant is exercised via cashless exercise, the Warrant Shares issued
pursuant to any such exercise shall be issued free of all restrictive legends. If at any time following the date hereof the Registration
Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not
otherwise available for the sale of the Warrant Shares, the Company shall immediately notify the holders of the Pre-Funded Warrants in
writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration
statement is effective again and available for the sale of the Warrant Shares (it being understood and agreed that the foregoing shall
not limit the ability of the Company to issue, or any holder thereof to sell, any of the Warrant Shares in compliance with applicable
federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Securities Laws Disclosure; Publicity</U>. At the request of the Representative, by [9:00 a.m. (New York City time) on the date hereof,
the Company shall issue a press release disclosing the material terms of the Offering, and neither the Company nor any Underwriter shall
issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any
press release of such Underwriter, or without the prior consent of such Underwriter, with respect to any press release of the Company,
which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing
party shall promptly provide the other party with prior notice of such public statement or communication. The Company and the Representative
shall consult with each other in issuing any other press releases with respect to the Offering, and neither the Company nor any Underwriter
shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect
to any press release of such Underwriter, or without the prior consent of such Underwriter, with respect to any press release of the
Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the
disclosing party shall promptly provide the other party with prior notice of such public statement or communication. The Company will
not issue press releases or engage in any other publicity, without the Representative&rsquo;s prior written consent, for a period ending
at 5:00 p.m. (New York City time) on the first business day following the 45th day following the Closing Date, other than normal and
customary releases issued in the ordinary course of the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Underwriter of the Securities is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business combination,
poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
adopted by the Company, or that any Underwriter of Securities could be deemed to trigger the provisions of any such plan or arrangement,
by virtue of receiving Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Option Shares pursuant to the Option and Warrant Shares pursuant to any exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
<U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all
of the Closing Shares, Option Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Closing
Shares, Option Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common
Stock traded on any other Trading Market, it will then include in such application all of the Closing Shares, Option Shares and Warrant
Shares, and will take such other action as is necessary to cause all of the Closing Shares, Option Shares and Warrant Shares to be listed
or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue
the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing
and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock
for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any
agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until ninety (90) days after the Closing Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been
issued and regardless of whether such agreement is subsequently canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.18 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19
<U>Research Independence</U>. The Company acknowledges that each Underwriter&rsquo;s research analysts and research departments, if any,
are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal
policies, and that such Underwriter&rsquo;s research analysts may hold and make statements or investment recommendations and/or publish
research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby
waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect
to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research
departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter&rsquo;s investment
banking divisions. The Company acknowledges that the Representative is a full-service securities firm and as such from time to time,
subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short
position in debt or equity securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULT
BY UNDERWRITERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">If
on the Closing Date or any Option Closing Date, if any, any Underwriter shall fail to purchase and pay for the portion of the Closing
Securities or Option Shares, as the case may be, which such Underwriter has agreed to purchase and pay for on such date (otherwise than
by reason of any default on the part of the Company), the Representative, or if the Representative is the defaulting Underwriter, the
non-defaulting Underwriters, shall use their reasonable efforts to procure within 36 hours thereafter one or more of the other Underwriters,
or any others, to purchase from the Company such amounts as may be agreed upon and upon the terms set forth herein, the Closing Securities
or Option Shares , as the case may be, which the defaulting Underwriter or Underwriters failed to purchase. If during such 36 hours the
Representative shall not have procured such other Underwriters, or any others, to purchase the Closing Securities or Option Shares, as
the case may be, agreed to be purchased by the defaulting Underwriter or Underwriters, then (a) if the aggregate number of Closing Securities
or Option Shares, as the case may be, with respect to which such default shall occur does not exceed 10% of the Closing Securities or
Option Shares, as the case may be, covered hereby, the other Underwriters shall be obligated, severally, in proportion to the respective
numbers of Closing Securities or Option Shares, as the case may be, which they are obligated to purchase hereunder, to purchase the Closing
Securities or Option Shares, as the case may be, which such defaulting Underwriter or Underwriters failed to purchase, or (b) if the
aggregate number of Closing Securities or Option Shares, as the case may be, with respect to which such default shall occur exceeds 10%
of the Closing Securities or Option Shares, as the case may be, covered hereby, the Company or the Representative will have the right
to terminate this Agreement without liability on the part of the non-defaulting Underwriters or of the Company except to the extent provided
in Article VI hereof. In the event of a default by any Underwriter or Underwriters, as set forth in this Article V, the applicable Closing
Date may be postponed for such period, not exceeding seven days, as the Representative, or if the Representative is the defaulting Underwriter,
the non-defaulting Underwriters, may determine in order that the required changes in the Prospectus or in any other documents or arrangements
may be effected. The term &ldquo;Underwriter&rdquo; includes any Person substituted for a defaulting Underwriter. Any action taken under
this Section shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Indemnification of the Underwriters</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless
the Underwriters, and each dealer selected by each Underwriter that participates in the offer and sale of the Public Securities (each
a &ldquo;<U>Selected Dealer</U>&rdquo;) and each of their respective directors, officers and employees and each Person, if any, who controls
such Underwriter or any Selected Dealer (&ldquo;<U>Controlling Person</U>&rdquo;) within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever (including but not limited
to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced
or threatened, or any claim whatsoever, whether arising out of any action between such Underwriter and the Company or between such Underwriter
and any third party or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other
statute or at common law or otherwise or under the laws of foreign countries, arising out of or based upon any Proceeding, commenced
or threatened (whether or not such Underwriter is a target of or party to such Proceeding), or arising out of or based upon any untrue
statement or alleged untrue statement of a material fact contained in (i) the Preliminary Prospectus, the Registration Statement, the
Prospectus or the Prospectus Supplement(as from time to time each may be amended and supplemented); (ii) any materials or information
provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Public Securities,
including any &ldquo;road show&rdquo; or investor presentations made to investors by the Company (whether in person or electronically);
or (iii) any application or other document or written communication (in this Article VI, collectively called &ldquo;<U>application</U>&rdquo;)
executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Public
Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, Trading Market
or any securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading, unless such statement or omission
was made in reliance upon and in conformity with written information furnished to the Company with respect to the applicable Underwriter
by or on behalf of such Underwriter expressly for use in the Preliminary Prospectus, the Registration Statement, the Prospectus or the
Prospectus Supplement, or any amendment or supplement thereto, or in any application, as the case may be. With respect to any untrue
statement or omission or alleged untrue statement or omission made in the Preliminary Prospectus, the indemnity agreement contained in
this Section 6.1 shall not inure to the benefit of an Underwriter to the extent that any loss, liability, claim, damage or expense of
such Underwriter results from the fact that a copy of the Prospectus was not given or sent to the Person asserting any such loss, liability,
claim or damage at or prior to the written confirmation of sale of the Public Securities to such Person as required by the Securities
Act and the rules and regulations thereunder, and if the untrue statement or omission has been corrected in the Prospectus, unless such
failure to deliver the Prospectus was a result of non-compliance by the Company with its obligations under this Agreement. The Company
agrees promptly to notify each Underwriter of the commencement of any litigation or proceedings against the Company or any of its officers,
directors or Controlling Persons in connection with the issue and sale of the Public Securities or in connection with the Registration
Statement, Preliminary Prospectus, the Prospectus or Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Procedure</U>. If any action is brought against an Underwriter, a Selected Dealer or a Controlling Person in respect of which indemnity
may be sought against the Company pursuant to Section 6.1, such Underwriter, such Selected Dealer or Controlling Person, as the case
may be, shall promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such
action, including the employment and fees of counsel (subject to the reasonable approval of such Underwriter or such Selected Dealer,
as the case may be) and payment of actual expenses. Such Underwriter, such Selected Dealer or Controlling Person shall have the right
to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Underwriter,
such Selected Dealer or Controlling Person unless (i) the employment of such counsel at the expense of the Company shall have been authorized
in writing by the Company in connection with the defense of such action, or (ii) the Company shall not have employed counsel to have
charge of the defense of such action, or (iii) such indemnified party or parties shall have reasonably concluded that there may be defenses
available to it or them which are different from or additional to those available to the Company (in which case the Company shall not
have the right to direct the defense of such action on behalf of the indemnified party or parties), in any of which events the reasonable
fees and expenses of not more than one additional firm of attorneys selected by such Underwriter (in addition to local counsel), Selected
Dealer and/or Controlling Person shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter,
Selected Dealer or Controlling Person shall assume the defense of such action as provided above, the Company shall have the right to
approve the terms of any settlement of such action which approval shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Indemnification of the Company</U>. Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company,
its directors, officers and employees and agents who control the Company within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company
to such Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions
made in the Preliminary Prospectus, the Registration Statement, the Prospectus or the Prospectus Supplement or any amendment or supplement
thereto or in any application, in reliance upon, and in strict conformity with, written information furnished to the Company with respect
to such Underwriter by or on behalf of such Underwriter expressly for use in such Preliminary Prospectus, the Registration Statement,
the Prospectus or the Prospectus Supplement or any amendment or supplement thereto or in any such application. In case any action shall
be brought against the Company or any other Person so indemnified based on the Preliminary Prospectus, the Registration Statement, the
Prospectus or the Prospectus Supplement or any amendment or supplement thereto or any application, and in respect of which indemnity
may be sought against such Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each
other Person so indemnified shall have the rights and duties given to such Underwriter by the provisions of this Article VI. <FONT STYLE="letter-spacing: -0.15pt">Notwithstanding
the provisions of this Section 6.3, no Underwriter shall be required to indemnify the Company for any amount in excess of the underwriting
discounts and commissions applicable to the Public Securities purchased by such Underwriter. The Underwriters&rsquo; obligations in this
Section 6.3 to indemnify the Company are several in proportion to their respective underwriting obligations and not joint.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Contribution Rights</U>. In order to provide for just and equitable contribution under the Securities Act in any case in which (i)
any Person entitled to indemnification under this Article VI makes a claim for indemnification pursuant hereto but it is judicially determined
(by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of
the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Article VI provides
for indemnification in such case, or (ii) contribution under the Securities Act, the Exchange Act or otherwise may be required on the
part of any such Person in circumstances for which indemnification is provided under this Article VI, then, and in each such case, the
Company and each Underwriter, severally and not jointly, shall contribute to the aggregate losses, liabilities, claims, damages and expenses
of the nature contemplated by said indemnity agreement incurred by the Company and such Underwriter, as incurred, in such proportions
that such Underwriter is responsible for that portion represented by the percentage that the underwriting discount appearing on the cover
page of the Prospectus bears to the initial offering price appearing thereon and the Company is responsible for the balance; provided,
that, no Person guilty of a fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section, each director,
officer and employee of such Underwriter or the Company, as applicable, and each Person, if any, who controls such Underwriter or the
Company, as applicable, within the meaning of Section 15 of the Securities Act shall have the same rights to contribution as such Underwriter
or the Company, as applicable. <FONT STYLE="letter-spacing: -0.15pt">Notwithstanding the provisions of this Section 6.4, no Underwriter
shall be required to contribute any amount in excess of the underwriting discounts and commissions applicable to the Securities purchased
by such Underwriter. The Underwriters&rsquo; obligations in this Section 6.4 to contribute are several in proportion to their respective
underwriting obligations and not joint.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Contribution Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice
of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made
against another party (&ldquo;<U>contributing party</U>&rdquo;), notify the contributing party of the commencement thereof, but the failure
to so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution
hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or
its representative of the commencement thereof within the aforesaid fifteen days, the contributing party will be entitled to participate
therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable
to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution
without the written consent of such contributing party. The contribution provisions contained in this Section 6.4 are intended to supersede,
to the extent permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VII.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Termination Right</U>. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date,
(i) if any domestic or international event or act or occurrence has materially disrupted, or in its opinion will in the immediate future
materially disrupt, general securities markets in the United States; or (ii) if trading on any Trading Market shall have been suspended
or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall
have been required by FINRA or by order of the Commission or any other government authority having jurisdiction, or (iii) if the United
States shall have become involved in a new war or an increase in major hostilities, or (iv) if a banking moratorium has been declared
by a New York State or federal authority, or (v) if a moratorium on foreign exchange trading has been declared which materially adversely
impacts the United States securities markets, or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane,
earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in the
Representative&rsquo;s opinion, make it inadvisable to proceed with the delivery of the Securities, or (vii) if the Company is in material
breach of any of its representations, warranties or covenants hereunder, or (viii) if the Representative shall have become aware after
the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material change in general
market conditions as in the Representative&rsquo;s judgment would make it impracticable to proceed with the offering, sale and/or delivery
of the Securities or to enforce contracts made by the Underwriters for the sale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Expenses</U>. In the event this Agreement shall be terminated pursuant to Section 7.1(a), within the time specified herein or any
extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Representative its actual and accountable
out of pocket expenses related to the transactions contemplated herein then due and payable, including the fees and disbursements of
EGS up to $25,000 (<FONT STYLE="letter-spacing: 0pt"><U>provided</U>, <U>however</U>, that such expense cap in no way limits or impairs
the indemnification and contribution provisions of this Agreement</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Article VI shall not be in any way effected
by such election or termination or failure to carry out the terms of this Agreement or any part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Preliminary Prospectus, the
Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and
thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge
have been merged into such documents, exhibits and schedules. Notwithstanding anything herein to the contrary, the Engagement Agreement,
dated November 12, 2025 (&ldquo;<U>Engagement Agreement</U>&rdquo;), by and between the Company and the Representative, shall continue
to be effective and the terms therein shall continue to survive and be enforceable by the Representative in accordance with its terms,
provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement
shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via e-mail attachment at the email address set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York
City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via
e-mail attachment at the e-mail address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Representative. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If either party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Article VI, the prevailing party in such Action or Proceeding shall
be reimbursed by the other party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the Option Closing, if any, and the
delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
the Underwriters and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at
law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14
<B><U>WAIVER OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST
EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVE FOREVER ANY RIGHT TO TRIAL BY
JURY. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement among the Company and the several Underwriters in
accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 204pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Apyx
Medical Corporation</B></FONT></TD></TR>
                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Matt Hill</I></FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Matt Hill</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 204pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apyx
Medical Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5115
Ulmerton Road</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clearwater,
FL 33760</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ruskin
Moscou Faltischek P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1425
RXR Plaza, East Tower, 15th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uniondale,
NY 11556-1425</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Adam Silver</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e-mail:
ASilvers@rmfpc.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
on the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LUCID
CAPITAL MARKETS, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Representative of the several</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters
listed on Schedule I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
LUCID CAPITAL MARKETS, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ John Lipman</I></FONT></TD><TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">John Lipman</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Head of Capital Markets</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucid
Capital Markets, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">570
Lexington Avenue, 40th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
John Lipman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e-mail:
JLipman@lucidcm.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellenoff
Grossman &amp; Schole</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1345
Avenue of the Americas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10105</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Robert Charron</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e-mail:
rcharron@egsllp.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; letter-spacing: -0.15pt">Schedule
of Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Closing Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Closing Warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Closing Purchase Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify">Lucid Capital Markets, LLC</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,762,431</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">9,400,000.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,762,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,400,000.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Writer&rsquo;s
Direct Dial: 516-663-6600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Writer&rsquo;s
Direct Fax: 516-663-6601</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
19, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apyx
Medical Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5115
Ulmerton Road</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clearwater,
Florida 33760</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Apyx Medical Corporation, a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the
preparation and filing with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) of a Prospectus Supplement,
dated November 18, 2025 (the &ldquo;<U>Prospectus Supplement</U>&rdquo;), to a Prospectus, dated December 2, 2022 (the &ldquo;<U>Prospectus</U>&rdquo;),
filed pursuant to a Registration Statement on Form S-3, Registration No. 333-268532 (the &ldquo;<U>Registration Statement</U>&rdquo;)
and filed by the Company with the Commission under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;).
The Prospectus Supplement relates to the issuance of: (a) 2,762,431 shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s
common stock, $0.001 par value per share (the &ldquo;<U>Common Stock</U>&rdquo;) and (b) 414,365 additional shares of Common
Stock granted to Lucid Capital Markets, LLC (the &ldquo;<U>Underwriter</U>&rdquo;) to cover the over-allotment (the &ldquo;<U>Option
Shares</U>&rdquo;) pursuant to an Underwriting Agreement, dated November 18, 2025, between the Company and the Underwriter (the &ldquo;<U>Agreement</U>&rdquo;).
The Shares and Option Shares are referred to herein as the &ldquo;<U>Securities</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agreement will be filed as an exhibit to a Current Report on Form 8-K and incorporated by reference into the Registration Statement.
This opinion is being rendered in connection with the filing of the Prospectus Supplement with the Commission. All capitalized terms
used herein and not otherwise defined herein shall have the respective meanings given to them in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this opinion, we have (i) examined and relied upon: (A) the Registration Statement, the Prospectus, and the Prospectus
Supplement, (B) the Company&rsquo;s Certificate of Incorporation and Bylaws, both as amended and currently in effect, (C) the
Agreement, and (D) the originals or copies of such records, documents, certificates, memoranda and other instruments and undertaken
such further inquiry as in our judgment are necessary or appropriate to enable us to render the opinions expressed below; and (ii) assumed
that the Securities to be sold by the Company will be sold at a price and on terms established by the Board of Directors of the Company
or a duly constituted pricing committee thereof in accordance with Section 153 of the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
to certain factual matters, we have relied upon information from officers and representatives of the Company and have not independently
verified such matters. In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on signed records,
instruments, certificates and documents; the authenticity and completeness of all documents submitted to us as originals; the conformity
to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials;
the legal capacity of all natural persons; the truth, accuracy and completeness of the information, representations and warranties contained
in the records, documents, instruments and certificates we have reviewed; and the due authorization, execution and delivery of all documents
where due authorization, execution and delivery are a prerequisite to the effectiveness thereof (except we have not made such assumption
with respect to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apyx
Medical Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
19, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are members of the Bar of the State of New York. Our opinion is limited to the General Corporation Law of the State of Delaware and,
as to the Pre-Funded Warrants constituting valid and binding obligations of the Company, the laws of the State of New York, and we express
no opinion with respect to the laws of any other jurisdiction. In addition, no opinion is expressed herein with respect to the qualification
of the Securities under the securities or blue sky laws of any state or any foreign jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the foregoing, and in reliance thereon, we are of the opinion that the Securities, when sold and issued in accordance
with the Purchase Agreement, the Registration Statement, the Prospectus and the Prospectus Supplement, will be validly issued, fully
paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth herein is as of the date hereof. We assume no obligation to advise you of changes that may hereafter be brought
to our attention. Our opinions herein are based on statutory laws and judicial decisions that are in effect on the date hereof, and we
do not opine with respect to any law, regulation, rule or government policy that may be enacted or adopted after the date hereof. We
do not express an opinion on any matters other than those expressly set forth in this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K in accordance with the requirements of Item
601(b)(5) of Regulation S-K under the Securities Act and to the use of this Firm&rsquo;s name therein and in the Prospectus Supplement
under the caption &ldquo;Legal Matters.&rdquo; In giving such consent, we do not hereby admit that we are in the category of persons
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ruskin Moscou Faltischek, P.C.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RUSKIN
    MOSCOU FALTISCHEK, P.C.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Apyx
Medical Corporation Announces Proposed Public Offering of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLEARWATER
FL, November 17, 2025 &mdash;Apyx Medical Corporation (Nasdaq: APYX)</B> (the &ldquo;Company&rdquo; or &ldquo;Apyx Medical&rdquo;) the
leader in surgical aesthetics marketed and sold as Renuvion&reg; and the AYON Body Contouring System&trade; (AYON), today announced that
it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject
to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or
terms of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucid
Capital Markets is acting as the sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange
Commission (&ldquo;SEC&rdquo;) on November 22, 2022, and declared effective by the SEC on December 2, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available
on the SEC&rsquo;s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the
offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York,
NY 10022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Investor
Relations Contact</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy
Feffer, Managing Director LifeSci Advisors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OP:
212-915-2568</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jfeffer@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>About
Apyx Medical Corporation</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apyx
Medical Corporation is a surgical aesthetics company with a passion for elevating people&rsquo;s lives through innovative products, including
its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring System<SUP>TM</SUP> in the
cosmetic surgery market and J-Plasma<SUP>&reg;</SUP> in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability
to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more
than 90 clinical documents. The AYON Body Contouring System<SUP>TM</SUP> is an FDA-cleared, groundbreaking, surgeon-designed body contouring
system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop
contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring
treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements
with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical
Corporation website at <U>www.ApyxMedical.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cautionary
Statement on Forward-Looking Statements</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company
believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance
that its expectations will be achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not
limited to, statements regarding the Company&rsquo;s anticipated public offering, including the completion of the public offering on
the anticipated terms, if at all, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial
items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency
or instrumentality including but not limited to the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;), supply chain disruptions,
component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those
matters on the Company&rsquo;s financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially
from those projected. Many of these factors are beyond the Company&rsquo;s ability to control or predict. Important factors that may
cause the Company&rsquo;s actual results to differ materially and that could impact the Company and the statements contained in this
release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company
is subject to, including the Company&rsquo;s ability to gain requisite approvals for its products from the FDA and other governmental
and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including
supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical
environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations;
and other risks that are described in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and
the Company&rsquo;s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company
claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of
1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information,
future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>ex99-2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Apyx
Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLEARWATER
FL, November 18, 2025 &mdash;Apyx Medical Corporation (Nasdaq: APYX)</B> (the &ldquo;Company&rdquo; or &ldquo;Apyx Medical&rdquo;) the
leader in surgical aesthetics marketed and sold as Renuvion&reg; and the AYON Body Contouring System&trade; (AYON), today announced the
pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering
price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucid
Capital Markets is acting as the sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the shares of common stock to be sold in the offering will be sold by the Company. In addition, the Company has granted the underwriter
a 45-day option to purchase up to an additional 414,365 shares of its common stock at the public offering price less the underwriting
discounts and commissions. The offering is expected to close on or about November 19, 2025, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use net proceeds from this offering for working capital and general corporate purposes. The offering is being made
pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on November 22, 2022, and declared effective by the SEC on December 2, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available
on the SEC&rsquo;s website at www.sec.gov. A final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement
and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC,
570 Lexington Avenue, 40th Floor, New York, NY 10022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Investor
Relations Contact</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy
Feffer, Managing Director LifeSci Advisors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OP:
212-915-2568</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jfeffer@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>About
Apyx Medical Corporation</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apyx
Medical Corporation is a surgical aesthetics company with a passion for elevating people&rsquo;s lives through innovative products, including
its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring System<SUP>TM</SUP> in the
cosmetic surgery market and J-Plasma<SUP>&reg;</SUP> in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability
to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more
than 90 clinical documents. The AYON Body Contouring System<SUP>TM</SUP> is an FDA-cleared, groundbreaking, surgeon-designed body contouring
system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop
contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring
treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements
with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical
Corporation website at <U>www.ApyxMedical.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cautionary
Statement on Forward-Looking Statements</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company
believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance
that its expectations will be achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not
limited to, statements regarding the Company&rsquo;s anticipated public offering, including the completion of the public offering on
the anticipated terms and the use of proceeds therefrom, projections of net revenue, margins, expenses, net earnings, net earnings per
share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals
from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;),
supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters
and the impact of those matters on the Company&rsquo;s financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially
from those projected. Many of these factors are beyond the Company&rsquo;s ability to control or predict. Important factors that may
cause the Company&rsquo;s actual results to differ materially and that could impact the Company and the statements contained in this
release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company
is subject to, including the Company&rsquo;s ability to gain requisite approvals for its products from the FDA and other governmental
and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including
supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical
environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations;
and other risks that are described in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and
the Company&rsquo;s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company
claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of
1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information,
future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form8-k_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form8-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "+ .$# 2(  A$! Q$!_\0
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M72+'X:O-Q W*%'N<UM7_ (4O1F-#6K'U1Q'@S_D:+?\ W7_E7>^(M.&IZ-/
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M>O7^]>2_%.*.?QKX2AE0/')-L=2.""Z@BM:%N?4RJWY=#T3PYK<7B'P]9ZG
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MG@]"*[_6=2BT?1KS49SB.VB:0^^!P/SJYQG&>?2O-/C'JKC2;#P_;R 3ZG.
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M=7T?PO=6U]J4%MI8N)+>&Z\DRS,WS,S$C<!Z9IJGUN+G/8<T!LUY@ND^*Y?
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MQNEZ1?ZAX^N_$.HZ<MG';0?9+0%@S2<G,AQT&.GUKK+RTCOK.:TG4M#,AC<
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>*%>>>5I)"HZ#)Z#Z5NT47?<+(!1112&%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !T ?0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y3QEX
MX\'?#O0;OQ7X^\6^%O WA:PDM(;[Q+XR\0:3X7\/V<U_=16-C!=ZUK=W8Z;:
MS7M[/;65G'-<A[J[N8((4,C . =717SK_P -?_LEC@_M1_LY@C@C_A=WPS'(
M]CXGX^G:C_AK_P#9+/3]J3]G/ _ZK=\,^I]?^*F/  /'!)[J 30!]%45YKX1
M^,GPD\?S+;^!/BG\-O&LSE/+C\)>._"OB260-W2'1M5O'/?;@G< .AR*]'!.
MXJ3R!SP1V!SC *YST;/;#-U( ^L[6-*L==TG4]$U2!+G3=9TZ^TG4+>0 QSV
M6I6LME=0NI(#)+!/)&X)Y5B!DD Z--?.TX 8X;"G@,=IPN>V\X3/4;N.<4 ?
MQ,^.O"%Y\/O'7C7P'J"NM[X+\6>(O"=SYFX.\GAW5;G2A+AP'"SQ6T<Z!@,+
M*"O!-<N3@$^@S7Z!?\%./AX/ O[6?BO5;>W\C3OB5X?\.^/;0+&R127CV0\.
MZ\RYRIEFU30IK^X"G(EO07 #KG\^\_*23TP<XZ< GCC.TY&,C.,$]30!^B7_
M  2[^'?_  G7[5VBZS<VYETSX8^%/$/CN=V4F$:HWV3PMH46_:56<W6OW%_;
M[B-ZZ1=%?]2^/Z?8^%'NH/L,DG '8#HH!.$"CJ#7XY?\$>/ARNG?#/XI_%*Z
MMPD_C'QC9>$M+F="))-'\%V/VRZ>&0LP:UFUOQ%>6Y*':9]-D1LL@Q^QX!&<
MDDGN?\@ =@HP !QU- "T5Y]XZ^*_PQ^%MI8:A\4?B1X ^&UAJMU+8Z5>^/O&
M/ASP?:ZG>P0FYGL]/N?$.IZ=!>W4%L4FF@MGDEC0/(T:QX8>;?\ #8'[)7_1
MTG[.?_A[_AE_\T] 'T517SK_ ,-@?LE?]'2?LY_^'O\ AE_\T](?VP/V2\?+
M^U)^SEGG&?C=\,^P)/'_  DXSP#QD#U('- 'T717.>$O&'A/Q[X?T_Q7X'\4
M>'/&?A?55F?2_$GA/7-,\1^']22WN);6=]/UG1[J]TV\6"Y@FMIS;7,JPW$4
ML#L)(W4='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7\YW_!UJ!_PY%_:<.!D>-_V="/8_\ "_/A\,CT."1GK@XZ
M5_1C7\Y__!UI_P H1?VG/^QV_9T_]7[\/: /\C^E*D $@@'.#V."0>?J#0#@
M@XSCMP?ID$$$>H(.:_O&_P"#:[_@B/\ \$W/^"B7_!/?Q3\>/VL_@9K7Q&^*
M&E_M-?$?X=67B#3_ (O?%_P-!%X1T#P/\+=:TK3/[&\#^-_#^B.]MJ'B;5YV
MOY-.?49_M"17%U+!;P1Q@'\).F:IJVBW<.I:-J.HZ3?6TB2V]_IEY<V%W;RQ
ML&CDANK62*:*2-]K(Z2*R-@J0<&OZ!/^"9G_  <?_P#!0?\ 8'\<>%M+\=_%
M;QO^U5^S9#>6-IXN^#'QI\7:KXOUC3_"UO$EI(GPF^(7B.?5/$G@'5-)L5$F
MB:/'?7G@:26W2WO?#3+</<V_TA_P<M_\$3_V??\ @E7XA_9X^)_[*NL^-X_A
M-^T!=?$3PYK'P\\>:_%XKN_ 'B_P%9^%=2LY?"WB.>TMM:U/PSXFTGQ+>FYL
MO$,FK:EH>J:)-,-<OK36K.PTC^5M3@@\_AU^@.#@GL<'!YQQ0!_O"_LY_'WX
M9?M3_ OX5_M%_!C7F\2_"SXR>#-&\=^"-8EMY+*]FT;6K5)A9:MI\I:;2]=T
M>Z%SHVO:3.S7&EZS87UA<$SV\A/M#_=/!/#<*<,?E/"MSACT!]<8P<$?RN?\
M&>7C[Q!XP_X)#7.@ZU=2W.G?"W]J[XT> ?"<4I.+'P[?Z!\-?B5+:PALXA_X
M2;XB>([K:&8*]TZAN,#^J4<@4 ?BQ_P6,^'9O/!_P=^+%M J2>&O$6O^!=7N
M(XLR26/BZTL]:TMYW P\=CJ/AG4(K6.4[2^L3D M*^?P0>18XI)'X2-2[X/
M"C)4-W("E5?JVWS#R:_K;_;P^'1^)W[)_P 9= @MUN-2TKPPWC;1E*[G&I>!
M;NV\4K'$ "<WMGIEYITF 28;R1%&YA7\O7P*^'Q^+WQE^%GPXV/+;^-/&V@:
M9J*ID%=&^T_VEXAEC8*^#'H]IJ$KL5552&4_($.0#^J3]C;X<'X4_LR?!OP;
M-;BVU&+P?9Z_K<8C$;?V[XOEG\6:P)/D4EX;_6I+3Y\N%MUB;(A4U].4Q% Q
MM"K'MQ$$&U1&,!0!@!<*%7 ^4*J!0-IR^@#^(G_@]T51^RI^Q"P50P_:#^(
M!  .#\-XLC.,\[$S[*HZ 8_SA:_T?/\ @]U_Y-2_8B_[.$\?_P#JMTK_ #@_
M\_3_ "* %P?\_P">W?T[T^)'D<)&ADD8JJ1J"S.[.JJBH/F=G)"A4!8DX ZD
M?Z5O_!(G_@W;_P""2G[5O_!-3]C[]HGXX_LW:]XK^+7Q7^%$?B7QWXCM/CI\
M=_#5OK.M-XBUO3S>IH?ASXBZ9H6F VUG;(+;2].LK0%"_D>8[,?TT\._\&NO
M_!$[POX@T+Q-I'[*&OQZMX=UC3-=TM[K]H;]H>_M4U'2+V#4+)KFQN_B?/:7
MENMS;QF:UNH9;:XCW0SQ21NRD _23_@F3^SK'^R9_P $]OV-?V=VT^#3-7^&
M7[//PSTSQC:VT<<4#_$;5O#=EXD^)M\D<4<8']I_$'6O$NI,9 \[M=%[F:XG
M:2>3[GIJC Q@#V P           H[* "2<DNH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^<_P#X.M/^4(O[3G_8
M[?LZ?^K]^'M?T85_.?\ \'6G_*$7]IS_ +';]G3_ -7[\/: /\C^OZR_^")G
M_!R+\./^"2_['/B#]F+Q/^ROXW^-&K:U\<?&WQ=C\6^'_BCH/@[38K7Q5X5\
M!^'8-$;3-2\':[=^?9OX.DN)KK[3(DJ7T>R-#&5;^30#/^3_ $_SZ\5]C^%?
M^"?W[8?CG]D;Q=^W;X,^!GB?Q;^REX!\::C\/_&WQ8\-ZAX7UF'PEXDT>QT+
M4=5/B/P=8:]/\0M'\.Z=:>)M#DO/&5]X3@\'6\FHP6\^O1W(DBC /O7_ (+5
M?\%K?BE_P60^)OPPUS7_ (8:)\#OA%\#M,\5V?PN^%NE>))O&FJPZKXYET)_
M&/B_QEXWFT'PNOB'6M8A\(^&+&RLK/P[I>E>'=*TO[/8Q7%[?ZWJVI?B-&K,
MV%&3C..><$8&!R26VA5&2S$ <X-(5*-M88((R,@]<'KR.A]\=QVK^^#_ (-8
M_P#@G%_P24_:4T6/]IZ^UWQO\>?VS/V?M3T"]\:?!#XU:/X7T_X<_"#Q#?V]
MXWACXD^"? ^EMJMK\4-$N]3M=4G\*>,_%NO7S^'_ !%HEG=7'@/PKXFL]#UO
M4@#^E#_@W=_8K\5_L,_\$J?V?OAK\2-$O/#7Q6^(DWB3X]_$SP[J,%Q9ZIX=
M\0?%2ZM]0T+P]K.GW4C2Z=KWA_X>V'@K1-?TZ6.WDL];T_4(9[:*X68']0?C
MS\>_#?P M/A)J'BI0NG?%7X]_"CX V5R\ZP+9>)/C!K,GA7P@_,4@FDO?%,V
MD:.EME"[ZG$XD4@*WO,8(!)^\QW-QSN( Y/4G"@9);&-H( ")_.-_P '1?QK
MU[]G?_@G/\,OC%X6NI+/Q/\ #[]NO]DWQYX=N8F9);?7OAMXMUGXFZ/,DB_.
M'@O_  ;;3(R E'C4IG&0 ?T7W=I;ZA:76GW\<=Q97MK/97UN_P J36MW"\%S
M%(H&=DL;NIPP\S>P4#"X_G[_ ."='P!NO#O[;?Q@AU:&0P?L[CQ]H-K<,C*D
MNKZQKMWX1\/WR[I,E+_PA'K5]!O,@"3!U'F/YE?O#X \9:+\1_ G@KXB>&9?
MM/AWQ_X2\-^-]!N1)O6XT;Q9I%KX@TR>-]O(EL]1@E638,_=557"CD/ GP>T
M'P%\0?C-\0=,\LZG\9?$'AC6]6401Q?91X:\)V'AVWMRRY,XGOHM1U61B5"R
MZBXY*$L <S^U=^T-X4_9._9R^,'[1?C/RW\/_"CP=>^(Y[22X6U&J:D\MOI?
MA[1%N'#""77/$.HZ5I$#[&82WL85&8@'Z%&06!.<$C/J 2 3@  \<@#&X$C
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M+G_!/[V^$>O]CU/Q/\=8 ]2=K' YPI/09K]HZ "BBB@ HHHH **** "BBB@
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M58,H8'((!!QQ@YP>^ <'!S@X//% #J*0L/4=0O7N<<8')/.=HY/;K2$[>6(
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M2MK/@[6O#^OVPL=;TFQO/+M-4@CN!$T%TLT$C1U]#AO[RLH ))92J@ 9))/
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M0&(!10'RS!4&TC#?,0 5/0\3$A1DD #J2>!VZG^M "T4AR.O'!/*D\#&3Q@
M#.#Z=^HJ-75F*HVXIRVT,5YXP3@@.<$X)&3G &,D EHHYZX/Y'CZ^G0YST[T
MAR.O'..5;J3@#/ R<C ]P.M "T4G/O\ ]\-_C30V3@,"?0*<]0.F?4@?4@=Z
M 'T4TDCEN![JRC\SQ[^^,=:7(]1_D \_@0?ISTH 6BFAL_=#,,XW*I9>N#R,
MC@Y!]"".HH=A& 6XR<#U/T_SZ4 .HIH8'/4$'!!!!S\IQCK_ !+CUW#U&4+
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MB#:_#OXC_"?P[I/B_3O'6CZ!+/K-C9^&CINO>(K/3KW0O#U]%XDO=,L[\ \
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M'[%_[(EAX(6+_A"[3]E_X VWA(P1I%$_AF'X5>%!H;HD:JH233C!)M&5#.6
M#_, #X+^)_\ P1P\'P^'KG5/V1OVR?V^?V0?C-IT,][X4\?Z;^V)^T-^T+X,
MNO$"HCZ>GQ)^$/[2?Q&^*/A/QSX6:]B235-#L3X7O]3BEFM1K,,,GDM\A_\
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M;I^H:?>M:SQ7'V.[MX;@0NKF,"OVQ^#'[5_[-?[26N>/?#G[/7QR^&/QOO\
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MD$'D$'(HIF!N<CD,[,,D#'.",-G'S YVA1G.0S;G<H _A'_X.7?B?X-\+?\
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M/CSPZ)I-1\(>+]$F,MKJ^B:ND$Z2QK<VTEUI]U:7MQ^%/_!1WQ)X7_X*@_\
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M (.KOA'\,?C_ /#7]BGX)_#K3='\0_\ !2'Q_P#M7?#S0OV6M%\*/8GXR0^
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M^AQW;A(&U35K1]<U>\EAA#8\VXMM(U&^,2[G6!'8 PHCU]/?M7?\$H_V>_\
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MN@?&[X3Z5<,G@"3PAXVUB\7PIJ_B;0M-=O#.D66G:I):>/?">F^'_%'@B_\
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M#X2_M ?'G]KK]FW3?$GA?3_C+^R=\7X_ 'B+X<_VY"_C+4_!FH_#_P !^,M
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M3/ GC?Q!X?M)/$5U\/[K5S+J6A:MHSOXC^&WBJYB\7^%WFCN?$WA[Q9\;_\
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>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? )@# 2(  A$! Q$!_\0
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M)"/R#]#WJMH?BF>_U9]/O+=(9!N"[6)^9>H_SZ5HL33=K/<S>'J*]UL=92<
M&C-8WB'6QHNG^<J"21V"HI.,G_\ 5FMIS4(\S,HQ<Y66YLTAZUS<&L:I<>&_
M[3CM8C-DL(@3\R>OU[T[PWXF76?,BE18KA?FVALAE]162KPNEW-'0G9OL='V
MI:KW5S%9VTEQ,P6-%+,3V%<OH_B>]UG4VBBM(TMURS.6)(7L/J:J56,9*+W9
M,:4I1<ELCL!C%%96GZC)=W#QNB@ 9!!^G^/Z&M6M(R4E=$236C%HHHJA#<5%
M-*L,+R.0JJ"Q)["I>E<IXXU(VFF"T1L/<G!]D'7^@_&L:T_9P<C2C3=2:BC
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M'4K7R[-6$-IIP=8W9A@M)N^]["J5C\-K*YN=0O\ Q&!=7]Y=/+NM[B5$2/\
MA3@KG KL+C4K>UU*RL)"_G7GF>5A<CY%RV3VXJ077^FFU,<HQ&)/-*?(<DC;
MN_O<=*?,UL+E1PC> ;^'PAX@\-VUU;BTO+@26&]F)A4LK,K<?[/&,]:UM.M_
M'4%Q:QW5QH#6BLHE$<<V\H.NW)QG%=69%'5@.<=>]*9%4X+ '&<$T<S8<J)*
M*J65];ZC#Y]K()(]Q7=@CD5;J2PHHHH RO$-M-=^'=2MK=-\TUI+'&G]YBA
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?&O0**?,PY2***.!-L4:1KUVJN!4U%%24%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? )@# 2(  A$! Q$!_\0
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M)"/R#]#WJMH?BF>_U9]/O+=(9!N"[6)^9>H_SZ5HL33=K/<S>'J*]UL=92<
M&C-8WB'6QHNG^<J"21V"HI.,G_\ 5FMIS4(\S,HQ<Y66YLTAZUS<&L:I<>&_
M[3CM8C-DL(@3\R>OU[T[PWXF76?,BE18KA?FVALAE]162KPNEW-'0G9OL='V
MI:KW5S%9VTEQ,P6-%+,3V%<OH_B>]UG4VBBM(TMURS.6)(7L/J:J56,9*+W9
M,:4I1<ELCL!C%%96GZC)=W#QNB@ 9!!^G^/Z&M6M(R4E=$236C%HHHJA#<5%
M-*L,+R.0JJ"Q)["I>E<IXXU(VFF"T1L/<G!]D'7^@_&L:T_9P<C2C3=2:BC
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M'4K7R[-6$-IIP=8W9A@M)N^]["J5C\-K*YN=0O\ Q&!=7]Y=/+NM[B5$2/\
MA3@KG KL+C4K>UU*RL)"_G7GF>5A<CY%RV3VXJ077^FFU,<HQ&)/-*?(<DC;
MN_O<=*?,UL+E1PC> ;^'PAX@\-VUU;BTO+@26&]F)A4LK,K<?[/&,]:UM.M_
M'4%Q:QW5QH#6BLHE$<<V\H.NW)QG%=69%'5@.<=>]*9%4X+ '&<$T<S8<J)*
M*J65];ZC#Y]K()(]Q7=@CD5;J2PHHHH RO$-M-=^'=2MK=-\TUI+'&G]YBA
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?&O0**?,PY2***.!-L4:1KUVJN!4U%%24%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>apyx-20251117.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCOWbP9z5Z8yekhvWB2bWmKnyAsyrW2RS1Rawp2YdQP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:APYX="http://apyxmedical.com/20251117" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20251117">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://apyxmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="apyx-20251117_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="apyx-20251117_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>apyx-20251117_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>apyx-20251117_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="apyx-20251117.xsd#Cover" roleURI="http://apyxmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://apyxmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX
MEDICAL CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115
Ulmerton Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>apyx-20251117.xsd</File>
    <File>apyx-20251117_lab.xml</File>
    <File>apyx-20251117_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form8-k_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "APYX",
   "nsuri": "http://apyxmedical.com/20251117",
   "dts": {
    "schema": {
     "local": [
      "apyx-20251117.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20251117_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20251117_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://apyxmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001493152-25-024279-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-024279-xbrl.zip
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MX,,^L(>$>LAT3'@1T=!NTV'<%7(H<I2:L]8F*O9_*5%@Z#MB*'*4,K3&8L/
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M7H&,8*N7V.-SDV3B1&G-]1*T4 E^6!3'H/W*;K(WIX5!3VN@(,.(+4?3RKI
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M/J$X34Q@V%U)'W\HA,UF[+.MDVPA\\[AC\(/@H=K;".PL\5<[X0HFL&!7;(
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M:/48.JHS-#(LD%XXP9LBF=L$N;40W3%I'+E_$3AYV&W'B%U1_3SK0)-V:>/
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M1W($%DR%#JB$J;I>_]#X$!Y:-(_X<U(<D44T-_ZAQ#A81?H28Z3\M7F^V?*
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MR8QZKN_&<90V)U'O5%2VC):HZRV7 ]+X5*3M-,,+>J@:BBB&"B- 2IZ_( ]
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M209!;78RHIA"[]W]%YQNV,V@+B((/![V9B_J5MC\/CT?G+HYCS.3-!,F?AR
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M$7R+V[&A8Z]AO_KWJ+'$Q^/1GUI7XTQA&;@L;<J(]D7*(1.B>".-:_K.D;=
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M"(0#=YMT\&=Q?(B'6JY,SSR_\37OA+E=M]SB'+/8%#]N)J2Y<#EQQ=25$,P
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M;:O?"Z \+Q(2.IPZ?1B+U(18(%8+$F+3&>E#5/.DEX^*))^H293GV_E+3A,
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M*,=R"8+/:[ 3(-=ERG8GY+=;GP1MTK%K-.WG4\M:6(XW32//R^*<:N=_-^_
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M.HS]!95,,TN-Y53*:CZ@D(F] D_+]AC%_.R;J?_9)\2I6JA8[C,#7KU^08/
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MVM"C=.*Q2Q$T1'1 R$)M[0ZSHKQHL?G:HH^<WW3I0O_&W9@ V(ELS989#0+
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M-N8XSN0U-(8"X'1OV:39OJY9T $HZ?.HF(2UFOZH:9K&J"/+7'68](93($'
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M!;\T6 /]$#TP G4% CONLW6^ ;5_O_>V\]U.C^DYW%<_V-;>7768FJ!5#1U
M4 BI31K<=-B_MS?1QC'X,+OE42Y8!M'M'DU^:16,=4L;D6[7)QOLN]YWG9V]
M7<;#4)(M$'V>6;#B5K=;=CF;*3@#E =Q1WD@0S;@F318<,[5C3!PN]%HL,K
M1S++G>T(EO8'D0">[RQ&'P!&46JL7E=(7&3$&+AXJ*XE%TU8N1E%\]%,"1=J
M[)%(Z["),'=")$O.19JAZQKGJQR5I!M<Q7%IJ3C&RSNPCA)3H933X5PH 8""
M5S[FC$1]TY-_363/)Y&-*8>4/@ TBB)XDH<J0IF$"3>R<M YR&%S/'@ED+TJ
MR/RA^[-U$YD4><TAG74204 B$P\MS6AI/4XB4C.9T!?X.!'D^HI0CMRL.0$6
M^<Z#33.X-6#L)CN"I(&+>N@#;BQ4#'3*-3X7_@R)DA128JVZDUJP4$QE4CT
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M>:P>;?RX15,YS>=$EU=**S(X^':"ZA17:#.-:VNB^^+4A(/J[P, W0D)/F5
MR2TP+%Q-@6M\N!RWZ)SZ0_CQ$'/W)[,<^VFPL:.J1M#@)"-_\Z"SV?'C:,2N
MS<OFN+6#^_<8,/8.MR_5NX@68=%MLMRFYI=^*6_18[U)THD;TX=*WW[Q1.TZ
MP*!FYC*Z227^@=J3ZQ6!5Z$2I?FT3P<?_9X:#S0PW?I4/72GB69)F3.#_(_^
M;[ZXYT2%Y'*!1@MT95VVW@6_3.\-A\>C'0ER>K;(M:^N!QMKMV2*WBJ2.D((
M.J8D/36FQ'G!&0&FZJ1Q83Q9ET8'=!879)Q_A_G>)SK=)QS8F?\%4$L! A0#
M%     @ V(-S6Q%1B<\J P  ZPL  !$              ( !     &%P>7@M
M,C R-3$Q,3<N>'-D4$L! A0#%     @ V(-S6R#[UB3]"@  ?X8  !4
M         ( !60,  &%P>7@M,C R-3$Q,3=?;&%B+GAM;%!+ 0(4 Q0    (
M -B#<UL8?[6>6P<  -I7   5              "  8D.  !A<'EX+3(P,C4Q
M,3$W7W!R92YX;6Q02P$"% ,4    " #8@W-;C/&)*YJF   V+00 "0
M        @ $7%@  97@Q+3$N:'1M4$L! A0#%     @ V(-S6Z:-Q<"8"P
M_S\   D              ( !V+P  &5X-2TQ+FAT;5!+ 0(4 Q0    ( -B#
M<UN:_D#C*@T  '8Y   *              "  9?(  !E>#DY+3$N:'1M4$L!
M A0#%     @ V(-S6Q=  "7W#0  OSP   H              ( !Z=4  &5X
M.3DM,BYH=&U02P$"% ,4    " #8@W-;U>L3-+ 6   /M   "P
M    @ $(Y   9F]R;3@M:RYH=&U02P$"% ,4    " #8@W-;2#\23M4:  "*
M&P  #P              @ 'A^@  9F]R;3@M:U\P,#$N:G!G4$L%!@     )
-  D &0(  .,5 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apyx-20251117.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2025-11-17</startDate>
            <endDate>2025-11-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-17" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-17" id="Fact000004">0000719135</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-17" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-11-17" id="Fact000010">2025-11-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-17" id="Fact000011">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-11-17" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-11-17" id="Fact000013">001-31885</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-11-17" id="Fact000014">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-11-17" id="Fact000015">5115 Ulmerton Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-11-17" id="Fact000016">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-11-17" id="Fact000017">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-11-17" id="Fact000018">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-11-17" id="Fact000019">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-11-17" id="Fact000020">384-2323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-11-17" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-11-17" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-11-17" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-11-17" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-11-17" id="Fact000025">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-11-17" id="Fact000026">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-11-17" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-11-17" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
